A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL).

Autor:	Hodson, D., Shouse, G., Shin, H., Salar, A., Bobillo, S., Ribrag, V., Macpherson, N., Cordoba, R., Kim, J. S., Radford, J., Guidez, S., Herrera, A. F., Morchhauser, F., Johnson, D., Izuzquiza, M., Sambamurthy, N., Forcina, A., Gorgun, G., Chen, R., Younes, A.
Předmět:	NON-Hodgkin's lymphoma MANTLE cell lymphoma RITUXIMAB MUCOSA-associated lymphoid tissue lymphoma
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p562-564, 3p
Abstrakt:	Here, we report preliminary safety and efficacy data from a phase II study evaluating capivasertib in pts with R/R B-NHL (NCT05008055). Several PI3K inhibitors (PI3Ki) have been approved to treat relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL). B Introduction: b The PI3K/AKT/mTOR pathway is an established therapeutic target in indolent B-cell non-Hodgkin lymphoma (B-NHL). [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text